PDF(Pubmed)
Abstract：
Pembrolizumab has been associated with a high tumor response rate among high microsatellite instability (MSI-H) cancer patients. The efficacy and safety of pembrolizumab in the treatment of MSI-H gastric cancer (GC) patients aged ≥ 85 years have not been reported. This study reports the case of an 89-year-old woman diagnosed with stage IIA MSI-H GC based on her chief complaint of abdominal pain. We considered surgery, but it was contraindicated due to the patient\'s age and cardiovascular comorbidity. Therefore, we administered pembrolizumab after receiving approval from the ethics committee, and no significant adverse events were noted. The tumor was markedly responsive to pembrolizumab, and the computed tomography and endoscopic findings revealed a complete response. This is the first report on the efficacy and safety of pembrolizumab in the treatment of GC in an \"oldest old\" patient with MSI-H.
摘要：
在高微卫星不稳定性（MSI-H）癌症患者中，Pembrolizumab与高肿瘤反应率相关。pembrolizumab治疗年龄≥85岁的MSI-H胃癌（GC）患者的疗效和安全性尚未见报道。这项研究报告了一名89岁的女性，根据她的腹痛主诉被诊断为IIAMSI-HGC期。我们考虑过手术，但由于患者的年龄和心血管合并症，它是禁忌的。因此,我们在获得伦理委员会批准后服用了派博利珠单抗，且未发现显著不良事件.肿瘤对pembrolizumab有明显反应，计算机断层扫描和内窥镜检查结果显示完全缓解。这是关于pembrolizumab治疗“年龄最大”的MSI-H患者GC的疗效和安全性的第一份报告。
